title: Changes of HDL subfraction concentration and particle size by intralipid in vivo.
abstract: The effects of the artificial triglyceride-phospholipid emulsion (10% intralipid) on HDL subfraction were studied in vivo. After a 14-h fast, subjects received intralipid via a 4-h infusion. Serum lipoproteins were analyzed before and at 4 and 6 h after the start of the infusion. At 4-h the following acute changes by infusion were observed. Triglyceride, phospholipid, free cholesterol, and esterified cholesterol in chylomicrons and VLDL increased. HDL2 as well as triglyceride, phospholipid, free cholesterol and protein within the HDL2 increased, while HDL3 decreased. An increase in HDL3 triglyceride was observed. The masses of apo A-I and A-II in the HDL2 density interval rose while these parameters fell in HDL3. There were decreases of apo C-II and C-III in the HDL subfractions and elevations in chylomicrons and VLDL. The particle size of the HDL subfractions increased. However, most of these acute changes at 4 h tended to disappear by 6 h. These results suggest that there is exchange of lipids and reversible transfer of apo C-II and C-III between HDL subfractions and intralipid, and conversion of HDL3 to HDL2 followed by the reverse conversion of HDL2 to HDL3 as the synthetic emulsion is cleared from the plasma.
authors.affiliation: Third Department of Internal Medicine, Medical School, Nagoya City University, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sakuma
authors.forename: C
authors.initials: C
authors.lastname: Lin
authors.forename: Y
authors.initials: Y
authors.lastname: Matsumoto
authors.forename: R
authors.initials: R
authors.lastname: Ikeuchi
authors.forename: T
authors.initials: T
authors.lastname: Ichikawa
authors.forename: H
authors.initials: H
authors.lastname: Hirata
authors.forename: Y
authors.initials: Y
authors.lastname: Noguchi
authors.forename: T
authors.initials: T
authors.lastname: Fujinami
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A / Q000097:blood; D001056:Apolipoproteins C / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D005217:Fat Emulsions, Intravenous / Q000097:blood / Q000494:pharmacology*; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3; D008297:Male; D010316:Particle Size
chemical_list: D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D053304:Apolipoprotein C-II; D053305:Apolipoprotein C-III; D001054:Apolipoproteins A; D001056:Apolipoproteins C; D002914:Chylomicrons; D005217:Fat Emulsions, Intravenous; D008075:Lipoproteins, HDL; D053439:Lipoproteins, HDL2; D053440:Lipoproteins, HDL3